產學研發徵求夥伴en文章

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16)

Description The licensing technology is about a proprietary Madin-Darby canine kidney cell line (NHRI sMDCK) capable of growing in suspension culture without serum. Further disclosed are culturing methods for growing the NHRI sMDCK cell line and methods for producing a vaccine from the MDCK cell line grown in the chemically defined medium. Traditionally, cell lines, …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: a CXCR4-Targeted Antagonist”(2019/07/24)

Title: NHRI technology, “DBPR807: a CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: DBPR807 is a potent antagonist targeting CXCR4 receptors for medical treatment of peripheral blood stem cell transplantation, hepatocellular carcinoma and acute myocardial infarction. Potential collaboration partner qualifications: be incorporated and approved by law and does not …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: a CXCR4-Targeted Antagonist”(2019/07/24) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy”(2019/07/24)

Title: NHRI technology, “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy” (abbreviated as “The Technology”) available for industry-academia collaboration technology licensing. Description: DBPR807 is a potent antagonist targeting CXCR4 receptors for medical treatment of peripheral blood stem cell transplantation, hepatocellular carcinoma and acute myocardial infarction. Potential collaboration partner qualifications: be incorporated and approved by …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy”(2019/07/24) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR114: a multi-targeted kinase inhibitor for solid tumors”(2018/12/13)

Title: NHRI technology, “DBPR114: a multi-targeted kinase inhibitor for solid tumors” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: DBPR114 is a novel small molecule multi-target kinase inhibitor. Multi-target drugs can more effectively inhibit cancer cell proliferation, overcome drug resistance, and show better and broader anti-cancer effects. DBPR114 significantly shrank tumor …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR114: a multi-targeted kinase inhibitor for solid tumors”(2018/12/13) Read More »